Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $146.37 USD
Change Today -3.58 / -2.39%
Volume 141.8K
BIO On Other Exchanges
New York
New York
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

bio-rad laboratories-a (BIO) Key Developments

Bio-Rad Laboratories, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides CapEx Guidance for the Full Year 2015

Bio-Rad Laboratories, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $472.8 million, down 7.2% compared to $509.3 million reported for the first quarter of 2014. On a currency-neutral basis, quarterly revenues increased 1.4% compared to the same period last year. Net income was $17.8 million, or $0.61 per share on a fully diluted basis compared to $6.7 million or $0.23 per share during the same period last year. Income from operations was $34,349,000 compared to $20,471,000 a year ago. Income before income taxes was $26,694,000 compared to $14,538,000 a year ago. Net cash generated from operations during the quarter was just over $29 million compared to $40 million last quarter and $66 million in the year-ago period. This decrease in cash flow versus last year is primarily the result of lower customer collections resulting from the decrease in reported sales, which includes more than $30 million of currency headwinds and receivables as well as increased employee-related payments associated with various 2014 incentive plans. Net capital expenditures for the quarter were slightly lower than expected at $27 million. For the full year 2015, the company's expectation for CapEx remains in the $130 million to $140 million range as it continue to invest in its global ERP system. The company continue to expect the full year effective tax rate to be in the 33% to 35% range.

Bio-Rad Laboratories, Inc. to Report Q1, 2015 Results on May 05, 2015

Bio-Rad Laboratories, Inc. announced that they will report Q1, 2015 results at 2:00 PM, Pacific Standard Time on May 05, 2015

Bio-Rad Laboratories, Inc., Q1 2015 Earnings Call, May 05, 2015

Bio-Rad Laboratories, Inc., Q1 2015 Earnings Call, May 05, 2015

Bio-Rad Laboratories, Inc. Announces Launch of Bioplex(R) 2200 25-OH Vitamin D Kit

Bio-Rad Laboratories, Inc. announced the launch of the BioPlex(r) 2200 25-OH Vitamin D kit for use on the company's BioPlex(r) 2200 system in U.S. markets. The assay offers a fully-automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum. The Vitamin D testing market has seen considerable growth over the past several years. In addition to the critical role Vitamin D plays in bone health, a number of recent studies have demonstrated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer. Based on data from a National Health and Nutrition Examination Survey several years ago, the CDC estimates that approximately 30% of the U.S. population has low levels of Vitamin D. The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system, providing clinical laboratories the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, helps consolidate workstations, and simplifies workflow.

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 28, 2015

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 28, 2015., at 04:00 Pacific Daylight. Location: corporate offices, 1000 Alfred Nobel Drive. Agenda: To consider and election of two directors by the holders of outstanding class a common stock and four directors by the holders of outstanding class B common stock; to consider a proposal to ratify the selection of KPMG LLP as independent auditors for the fiscal year ending December 31, 2015; and to consider such other matters as may properly come before the meeting and at any adjournments or postponements thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:US $146.37 USD -3.58

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $53.97 USD +0.23
BioMerieux €96.27 EUR 0.00
IDEXX Laboratories Inc $62.40 USD -0.73
QIAGEN NV €22.35 EUR +0.005
Siemens Ltd 1,428 INR +15.50
View Industry Companies

Industry Analysis


Industry Average

Valuation BIO Industry Range
Price/Earnings 44.0x
Price/Sales 2.0x
Price/Book 2.0x
Price/Cash Flow 36.2x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-RAD LABORATORIES-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at